Drug Profile
GS 4224
Alternative Names: GS-4224; Oral PD-L1 small molecule inhibitor - Gilead SciencesLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Non-small cell lung cancer
- No development reported Hepatitis B
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Hepatitis-B in New Zealand (PO, Tablet)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in New Zealand (PO, Tablet)
- 29 Apr 2021 Phase-I clinical trials in Non-small cell lung cancer in USA (PO) in April 2021 (Gilead Sciences pipeline, April 2021)